Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02482298 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

A Phase 2 study of Sickle Cell Disease, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
87
Enrollment target
20
Study locations

NCT02482298 is a Phase 2 study of Sickle Cell Disease that has completed, run by AstraZeneca. The registered enrollment target is 87 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02482298, a Phase 2 study of Sickle Cell Disease, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
87 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease

Conditions Studied

Sickle Cell Disease

Interventions

  • DRUG Placebo
  • DRUG Ticagrelor

Study Locations (20)

Other

  • Research Site - Alexandria
  • Research Site - Cairo
  • Research Site - Cairo
  • Research Site - Bordeaux
  • Research Site - Strasbourg
  • Research Site - Verona
  • Research Site - Kikuyu
  • Research Site - Kisian
  • Research Site - Nairobi
  • Research Site - Beirut
  • Research Site - Beirut
  • Research Site - Adana
  • Research Site - Mersin
  • Research Site - Van
  • Research Site - Harrow
  • Research Site - London
  • Research Site - London

Florida

  • Research Site - Miami

Maryland

  • Research Site - Bethesda

South Carolina

  • Research Site - Charleston

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2015-07-09
Est. Completion 2016-11-16
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02482298

The ClinicalTrials.gov registry entry for NCT02482298 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (70% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02482298 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT02482298 about?

NCT02482298 is a clinical study titled "A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease". The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease

What is the current status of trial NCT02482298?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2015-07-09. Estimated completion is 2016-11-16.

What conditions does trial NCT02482298 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT02482298?

The interventions under investigation include: Placebo (DRUG), Ticagrelor (DRUG).

Who is sponsoring clinical trial NCT02482298?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02482298 being conducted?

This trial has 20 study locations across Florida, Maryland, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.